Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance | Synapse
September 22, 2022Open Access
Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance
Key Points
Key points are not available for this paper at this time.
Abstract
Nct02092467.
AI से पूछें
Like
Bookmark
Share
View Full Paper
AI से पूछें
Like
Bookmark
Share
View Full Paper
Cite This Study
Charles‐Schoeman et al. (Thu,) studied this question.